AI English summary of an SEC filing — figures as filed
Boston Scientific BSXThe company said its wholly owned finance subsidiary, American Medical Systems Europe B.V., issued €2,000,000,000 of senior notes, of which €750,000,000 mature in 3.375% 2029 and €1,250,000,000 mature in 3.500% 2032, and that the company fully and unconditionally guarantees the notes.
Key points
AI summaryThe company said its wholly owned finance subsidiary, American Medical Systems Europe B.V., issued €2,000,000,000 of senior notes, of which €750,000,000 mature in 3.375% 2029 and €1,250,000,000 mature in 3.500% 2032, and that the company fully and unconditionally guarantees the notes.
The company said AMS Europe completed the notes offering on February 27, 2024, and that net proceeds after the underwriting discount and estimated offering expenses were about €1.980 billion.
The company said it plans to use the net proceeds, together with commercial paper borrowings and cash on hand, to fund the purchase price of the Axonics acquisition and related fees and expenses. It said any proceeds not used for that purpose would go to repaying the 3.450% senior notes due in March 2024 and paying accrued interest on them, as well as for general corporate purposes.
The company said AMS Europe will be required to redeem each series of notes at 101% of principal, plus unpaid interest, if the Axonics acquisition is not completed by January 8, 2025 (which may be extended under the merger agreement to no later than January 8, 2026) or by a later agreed date plus 5 business days, or if AMS Europe notifies the trustee that the company will not pursue the acquisition.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
€2,000,000,000 Senior Notes Issuance Structure
The company said its wholly owned finance subsidiary, American Medical Systems Europe B.V., issued €2,000,000,000 of senior notes, of which €750,000,000 mature in 3.375% 2029 and €1,250,000,000 mature in 3.500% 2032, and that the company fully and unconditionally guarantees the notes.
Source · Based on the filing body and exhibits
Offering Completed and Net Proceeds of About €1.980 billion
The company said AMS Europe completed the notes offering on February 27, 2024, and that net proceeds after the underwriting discount and estimated offering expenses were about €1.980 billion.
Source · Based on the filing body and exhibits
Use of Net Proceeds
The company said it plans to use the net proceeds, together with commercial paper borrowings and cash on hand, to fund the purchase price of the Axonics acquisition and related fees and expenses. It said any proceeds not used for that purpose would go to repaying the 3.450% senior notes due in March 2024 and paying accrued interest on them, as well as for general corporate purposes.
Source · Based on the filing body and exhibits
Special Mandatory Redemption if Axonics Acquisition Is Not Completed
The company said AMS Europe will be required to redeem each series of notes at 101% of principal, plus unpaid interest, if the Axonics acquisition is not completed by January 8, 2025 (which may be extended under the merger agreement to no later than January 8, 2026) or by a later agreed date plus 5 business days, or if AMS Europe notifies the trustee that the company will not pursue the acquisition.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…